Perrine Devic

Bispecific antibodies: advancing precision oncology

Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis

Description of neurotoxicity in a series of patients treated with CAR T-cell therapy

Antibodies to clustered acetylcholine receptor: expanding the phenotype